Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Phase I-part: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of ZK 219477 in combination with cisplatin To investigate the safety and tolerability of ZK 219477 in combination with cisplatin Phase II-part: To evaluate the anti-tumor activity of ZK 219477 in combination with cisplatin in patients with chemotherapy-naive, extensive-disease stage small cell lung cancer
Critère d'inclusion
- Extensive disease (ED) stage small-cell lung cancer (SCLC)